

CASE STUDY

Microbiome based therapeutic intervention: an assessment of efficacy

Objective

The customer was seeking to have a comprehensive coverage of literature-based information specific to microbiome based therapeutic intervention and effectiveness of probiotics, in two indications, Interstitial Bowel Disease, Non-Alcoholic Fatty Liver Disease.

Scope of the project


The scope of the project was to curate microbiome related papers with the primary focus on therapeutic interventional studies specific to two main diseases, IBD and NAFLD. The effect of probiotics in IBD and NAFLD were analysed on the basis of various parameters. These parameters were categorized into biochemical, molecular, microbial, histological and biomarkers. Response to sole probiotics as well as in combination with drugs were studied. The alterations observed in these parameters were curated meticulously and a detailed dataset was provided to the client. The representation of dataset in the form of Dashboard made it easy to access the precise information.

Search strategy

Curadigm used various search methods to identify papers that pertain to the project scope. All clinical and pre-clinical research articles related to the response to probiotics were reviewed. The true positive rate was increased by the use of search terminologies, such as MeSH and other standard vocabularies. As we progressed with curation, we continuously optimized search parameters.

Curation Process


We emphasize high quality deliverable through two level QC approach




Results

A study of about 56 probiotic strains was included in the information curated from 400 references. The information was presented through a dynamic dashboard.

Indication Vs Therapy Vs Drug Name Vs Pipeline Vs Pipeline



Indication	Therapy	Drug name	Pipeline	Pubmed ID
1. Non-alcoholic Fatty Liver Disease	Combination therapy	Galactooligosaccharide (GOS)	Lactobacillus, Bifidobacterium	29353414
2. Non-alcoholic Fatty Liver Disease	Combination therapy	Fructooligosaccharides	Bifidobacterium longum	21901256
3. Non-alcoholic Fatty Liver Disease	Combination therapy	S. miltiorrhiza Bunge polysaccharide	L. plantarum X; B. bifidum V	31950772
4. Non-alcoholic Fatty Liver Disease	Combination therapy	Clodronate liposome	Escherichia coli NF73-1	33363046



For more information, contact us at info@curadigmdata.com



Curadigm Dataalytics
 WeWork Salarpuria Symbiosis
 Bannerghatta Road
 Bengaluru 560076, India